TransEnterix Announces Launch of Underwritten Public Offering
05 Marzo 2020 - 3:15PM
Business Wire
TransEnterix, Inc. (NYSE American: TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
that it has commenced an underwritten offering of units. The
offering is expected to be comprised of (i) a unit of common stock
and warrants to purchase shares of common stock and (ii) a unit of
convertible preferred stock and warrants to purchase shares of
common stock. The unit of convertible preferred stock and warrants
is being offered in lieu of the unit of common stock and warrants
for those purchasers who would otherwise beneficially own more than
4.99% (or, at the election of the purchaser 9.99%). The preferred
stock to be issued in the offering, if any, includes a beneficial
ownership blocker but has no dividend rights (except to extent
dividends are also paid on the common stock),voting rights,
liquidation preference or other preferences over common stock.
Ladenburg Thalmann & Co. Inc. is acting as sole book-running
manager in connection with the offering.
A shelf registration statement relating to the units being sold
in this offering was previously filed with the U.S. Securities and
Exchange Commission on May 10, 2017 and was declared effective on
May 17, 2017. The offering will be made only by means of a
prospectus supplement and accompanying prospectus. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC and will be available on the
SEC's website located at http://www.sec.gov. When available, copies
of the preliminary prospectus supplement and accompanying
prospectus can be obtained at the SEC's website at www.sec.gov or
from Ladenburg Thalmann & Co. Inc., Prospectus Department, 277
Park Avenue, 26th Floor, New York, New York 10172 or by email at
prospectus@ladenburg.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor will there be any sales of
these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such jurisdiction.
About TransEnterix
TransEnterix is a medical device company that is digitizing the
interface between the surgeon and the patient to improve minimally
invasive surgery by addressing the clinical and economic challenges
associated with current laparoscopic and robotic options in today's
value-based healthcare environment. The Company is focused on the
market development activities for, and increasing utilization of,
its Senhance Surgical System, which digitizes laparoscopic
minimally invasive surgery. The system allows for robotic
precision, haptic feedback, surgeon camera control via eye sensing
and improved ergonomics while offering responsible economics. The
Senhance Surgical System is available for sale in the US, the EU,
Japan and select other countries. For more information, visit
www.transenterix.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements about the proposed public offering of
our securities. These statements involve significant risks and
uncertainties, including those discussed in the preliminary
prospectus supplement related to the offering and in our most
recent report filings with the SEC. Because these statements
reflect our current expectations concerning future events, our
actual results could differ materially from those anticipated in
these forward-looking statements as a result of many factors. There
can be no assurance that TransEnterix will be able to complete the
offering. We are providing this information as of March 5, 2020. We
undertake no duty to update any forward-looking statements to
reflect the occurrence of events or circumstances after the date of
such statements or of anticipated or unanticipated events that
alter any assumptions underlying such statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200305005848/en/
Investor Contact: Mark Klausner, +1 443-213-0501
invest@transenterix.com or Media Contact: Terri Clevenger, +1
203-682-8297 terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024